Patents by Inventor Baoqing Gong

Baoqing Gong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200039935
    Abstract: The present disclosure relates to a method of synthesizing 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine (ceritinib) and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing ceritinib.
    Type: Application
    Filed: October 8, 2019
    Publication date: February 6, 2020
    Inventors: Mark Clinton Davis, Baoqing Gong, Denis Har, Tobias Kapferer, Xuchun Zheng
  • Publication number: 20180057457
    Abstract: The present disclosure relates to a method of synthesizing 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine (ceritinib) and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing ceritinib.
    Type: Application
    Filed: March 4, 2015
    Publication date: March 1, 2018
    Applicant: Novartis AG
    Inventors: Mark Clinton Davis, Baoqing Gong, Denis Har, Tobias Kapferer, Xuchun Zheng
  • Patent number: 9868739
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salt(s) thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: January 16, 2018
    Assignee: Novartis AG
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Publication number: 20160175305
    Abstract: The present invention describes specific crystalline forms of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-yl-phenyl)-N-2-(isopropylsulfonyl)phenyl)-2,4-diamine. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.
    Type: Application
    Filed: March 2, 2016
    Publication date: June 23, 2016
    Applicant: Novartis AG
    Inventors: Lili Feng, Baoqing Gong, Piotr H. Karpinski, Liladhar Murlidhar Waykole
  • Patent number: 9359326
    Abstract: The invention relates to processes for manufacturing a compound of formula 5, or a stereoisomer, tautomer or a salt thereof, wherein the substituents are as defined in the specification. The invention further relates to new manufacturing processes for specific solid forms of Compound A and its salts, to such solid forms and to use of such solid forms for the therapeutic treatment of warm-blooded animals.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: June 7, 2016
    Assignee: Novartis AG
    Inventors: John Vincent Calienni, Baoqing Gong, Prasad Kapa, Hui Liu
  • Patent number: 9309229
    Abstract: The present invention describes specific crystalline forms of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropylsulfonyl)phenyl)-2,4-diamine. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: April 12, 2016
    Assignee: Novartis AG
    Inventors: Lili Feng, Baoqing Gong, Piotr H. Karpinski, Liladhar Murlidhar Waykole
  • Publication number: 20160039832
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salt(s) thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Application
    Filed: October 20, 2015
    Publication date: February 11, 2016
    Applicants: Novartis AG, ASTEX Therapeutics, LTD.
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Patent number: 9242971
    Abstract: The present invention relates to novel crystalline forms of salts of 2-((1R,4R)-4-(4-(5-(benzo[d]oxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: January 26, 2016
    Assignee: NOVARTIS AG
    Inventors: Christina Capacci-Daniel, Marilyn Delacruz, Baoqing Gong, Akash Jain, Yansong Lu, Lijun Zhang
  • Patent number: 9193732
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: November 24, 2015
    Assignees: Novartis AG, Astex Therapeutics, LTD
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Publication number: 20150232446
    Abstract: The invention relates to processes for manufacturing a compound of formula 5, or a stereoisomer, tautomer or a salt thereof, wherein the substituents are as defined in the specification. The invention further relates to new manufacturing processes for specific solid forms of Compound A and its salts, to such solid forms and to use of such solid forms for the therapeutic treatment of warm-blooded animals.
    Type: Application
    Filed: May 6, 2015
    Publication date: August 20, 2015
    Inventors: John Vincent Calienni, Dietmar Flubacher, Baoqing Gong, Prasad Kapa, Hui Liu, Pascal Michel, Rasmus Mose, Maria Caterina Testa
  • Publication number: 20150166522
    Abstract: The present invention relates to novel crystalline forms of salts of 2-((1R,4R)-4-(4-(5-(benzo[d]oxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Applicant: NOVARTIS AG
    Inventors: Christina CAPACCI-DANIEL, Marilyn DELACRUZ, Baoqing GONG, Akash JAIN, Yansong LU, Lijun ZHANG
  • Publication number: 20150099760
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: April 9, 2015
    Applicant: Novartis AG
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Patent number: 8987459
    Abstract: The present invention relates to novel crystalline forms of salts of 2-((1R,4R)-4-(4-(5-(benzo[d]oxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: March 24, 2015
    Assignee: Novartis AG
    Inventors: Christina Capacci-Daniel, Marilyn DeLaCruz, Baoqing Gong, Akash Jain, Yansong Lu, Lijun Zhang
  • Publication number: 20140200246
    Abstract: The present invention relates to novel crystalline forms of salts of 2-((1R,4R)-4-(4-(5-(benzo[d]oxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl)acetic acid and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 17, 2014
    Applicant: NOVARTIS AG
    Inventors: Christina CAPACCI-DANIEL, Marilyn DELACRUZ, Baoqing GONG, Akash JAIN, Yansong LU, Lijun ZHANG
  • Publication number: 20130274279
    Abstract: The present invention describes specific crystalline forms of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropylsulfonyl)phenyl)-2,4-diamine. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.
    Type: Application
    Filed: December 15, 2011
    Publication date: October 17, 2013
    Applicant: NOVARTIS AG
    Inventors: Lili Feng, Baoqing Gong, Piotr H. Karpinski, Liladhar Murlidhar Waykole
  • Publication number: 20130225571
    Abstract: The invention relates to new crystalline forms of processes for manufacturing a compound of formula 5, or a stereoisomer, tautomer or a salt thereof, wherein the substituents are as defined in the specification. The invention further relates to new manufacturing processes for specific solid forms of Compound A and its salts, to such solid forms and to use of said solid forms for the therapeutic treatment of warm-blooded animals.
    Type: Application
    Filed: September 29, 2011
    Publication date: August 29, 2013
    Applicant: NOVARTIS AG
    Inventors: John Vincent Calienni, Marilyn De La Cruz, Dietmar Flubacher, Baoqing Gong, Prasad Koteswara Kapa, Piotr H. Karpinski, Hui Liu, Pascal Michel, Rasmus Mose, Maria Caterina Testa, Liladhar Murlidhar Waykole
  • Publication number: 20130217698
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Application
    Filed: November 9, 2011
    Publication date: August 22, 2013
    Applicants: Astex Therapeutics LTD, Novartis AG
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Publication number: 20120115878
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 10, 2012
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Publication number: 20100189726
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Application
    Filed: September 29, 2009
    Publication date: July 29, 2010
    Applicant: Cell Therapeutics, Inc.
    Inventors: Lynn BONHAM, J. Peter Klein, Robert E. Finney, David M. Hollenback, Scott A. Shaffer, Norina M. Tang, Thayer H. White, David W. Leung, Baoqing Gong, John Tulinsky
  • Publication number: 20100004237
    Abstract: Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.
    Type: Application
    Filed: July 31, 2009
    Publication date: January 7, 2010
    Inventors: Timothy D. Machakewski, Cynthia M. Shafer, Christopher McBride, William Antonios-McCrea, Brandon M. Doughan, Barry H. Levine, Yi Xia, Maureen McKenna, X. Michael Wang, Kris Mendenhall, Yasheen Zhou, Baoqing Gong, Dan Gu, John Dolan, John Tulinsky, Kristin Brinner, Zhenhai Gao, Daniel Poon, Paul Barsanti, Xiaodong Lin, Abran Costales, Alice Rico, Nathan Brammeier, Teresa Pick, Paul A. Renhowe